Technique

No molecule left behind

Next-gen sequencing

We’re devoted to empowering focused and flexible genomic coverage, enabling ultra-high sensitivity and reducing costs.

Our technology is optimized to ensure low-frequency mutant molecule (<0.05%) detection with high specificity.

Our products are customizable for our BioPharma partners to focus on novel clinical biomarker hypotheses.

Next-gen sequencing
1 — 3

Focused and flexible

genomic coverage allows for ultra-high sensitivity and reduced costs.

2 — 3

No molecule left behind

Our technology is optimized to ensure low-frequency mutant molecule (<0.05%) detection with high specificity.

3 — 3

Customizable panels

Our products are customizable for our BioPharma partners to focus on novel clinical biomarker hypotheses.

Technology

Liquid biopsy assays designed for BioPharma clinical development

Read more about SafeSEQ

  1. Detect genetic alterations at very low mutant allele frequencies with purpose-designed, ultra-sensitive tests.

  2. Ensure the most efficient approach to patient enrollment in clinical trials for targeted therapies through reliable identification of even the lowest frequency mutations.

  3. Expert-designed SafeSEQ panels are cost-effective, ultra-sensitive NGS liquid biopsy solutions that aid in identifying tumor mutations across cancer types.

Read more about SafeSEQ

With SafeSEQ, 100% of the starting molecules are analyzed, which isn’t always the case with other methods or technologies. This chart shows that with SafeSEQ, the input molecules are not lost along the sequencing process like they commonly can be with other methods or technologies. The chart shows the sample input of benign molecules and mutant molecules remain intact throughout sample amplification, multiplexing, dilution, purification, and quantification. The second part of the chart shows that 40% of molecules could be lost during sample preparation prior to  ligation/hybrid-capture based next-generation sequencing (or NGS), which could lead to a false negative or inaccurate analysis.

General help line:

For more information on the data in the table, contact us at info@sysmexinostics.com

Commitment

Our loyalty to you

Pioneer

  1. We’re committed to delivering ultra-sensitive SafeSEQ panels through our CLIA-certified lab in as quickly as four weeks after design finalization.

  2. We offer experienced regulatory guidance to help you define the optimal diagnostic support strategy for your clinical development program.

  3. Our ctDNA molecular diagnostics experts can quickly assess your specific requirements and provide you with a range of options.

Biopharma Offerings

From pioneer to gold standard in liquid biopsy

This chart shows our Biopharma Offerings with a timeline starting in 2008 showing the progression to the current year of 2021. We offer lab services and single-site PMA in addition to the distributed kit. Our lab services include patient testing, clinical assay development, in vitro diagnostics (IVD), and CDx. We offer CLIA testing services to inform a physician of treatment options for patients, investigational testing for clinical assay development, testing for registration trials, and post-market patient testing. Applications are for patients and oncologists, co-development for pharma, testing for academic investigators, pharma in late Tx development, and clinical laboratories.

We have worked hard to optimize every step of the assay process, from sample collection through processing and bioinformatics to ensure industry-leading sensitivity down to single mutant molecules for our SafeSEQ liquid biopsy tests. Dr. Frank Holtrup, Director of R&D — Sysmex Inostics